Johannes, C. B., Beachler, D. C., Layton, J. B., Danysh, H. E., Ziemiecki, R. ., Arana, A. ., … Gilsenan, A. . (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3
A. Gilsenan
First name
A.
Last name
Gilsenan
Danysh, H. E., Johannes, C. B., Beachler, D. C., Layton, J. B., Ziemiecki, R. ., Arana, A. ., … Gilsenan, A. . (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4
Fortuny, J. ., Gilsenan, A. ., Cainzos-Achirica, M. ., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L. ., … Andrews, E. B. (2019). Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350. Drug Saf. http://doi.org/10.1007/s40264-019-00836-z
Gilsenan, A. ., Fortuny, J. ., Cainzos-Achirica, M. ., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L. ., … Andrews, E. B. (2019). Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-019-00835-0
Arana, A. ., Margulis, A. V., Varas-Lorenzo, C. ., Bui, C. L., Gilsenan, A. ., McQuay, L. J., … Perez-Gutthann, S. . (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150
Ruigomez, A. ., Plana, E. ., Gilsenan, A. ., Fortuny, J. ., Cainzos-Achirica, M. ., Flynn, R. W. V., … Andrews, E. B. (2021). Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride. Drug Saf. http://doi.org/10.1007/s40264-021-01044-4